BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32331932)

  • 1. Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.
    Yu W; Liu J; Yu Y; Zhang V; Clausen D; Kelly J; Wolkenberg S; Beshore D; Duffy JL; Chung CC; Myers RW; Klein DJ; Fells J; Holloway K; Wu J; Wu G; Howell BJ; Barnard RJO; Kozlowski J
    Bioorg Med Chem Lett; 2020 Jul; 30(13):127197. PubMed ID: 32331932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.
    Yu W; Fells J; Clausen D; Liu J; Klein DJ; Christine Chung C; Myers RW; Wu J; Wu G; Howell BJ; Barnard RJO; Kozlowski J
    Bioorg Med Chem Lett; 2021 Sep; 47():128168. PubMed ID: 34091041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity.
    Yu W; Liu J; Clausen D; Yu Y; Duffy JL; Wang M; Xu S; Deng L; Suzuki T; Chung CC; Myers RW; Klein DJ; Fells JI; Holloway MK; Wu J; Wu G; Howell BJ; Barnard RJO; Kozlowski J
    J Med Chem; 2021 Apr; 64(8):4709-4729. PubMed ID: 33797924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of latent HIV by histone deacetylase inhibitors.
    Shirakawa K; Chavez L; Hakre S; Calvanese V; Verdin E
    Trends Microbiol; 2013 Jun; 21(6):277-85. PubMed ID: 23517573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.
    Huber K; Doyon G; Plaks J; Fyne E; Mellors JW; Sluis-Cremer N
    J Biol Chem; 2011 Jun; 286(25):22211-8. PubMed ID: 21531716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
    Painter MM; Zaikos TD; Collins KL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
    Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
    AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
    Rasmussen TA; Lewin SR
    Curr Opin HIV AIDS; 2016 Jul; 11(4):394-401. PubMed ID: 26974532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal.
    Boateng AT; Abaidoo-Myles A; Bonney EY; Kyei GB
    AIDS Res Hum Retroviruses; 2022 Aug; 38(8):615-621. PubMed ID: 35778852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
    Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
    J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway.
    Lu W; Yang C; Xu X; Chen C; Hou X; Fang H; Liu S
    Life Sci; 2021 Feb; 267():118427. PubMed ID: 32941894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
    Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
    Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
    Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
    Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
    Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.